1 / 62

Traitements médicamenteux du SDRA

Traitements médicamenteux du SDRA. Laurent PAPAZIAN Réanimation médicale Unité de Recherche en Maladies Infectieuses et Tropicales Émergentes Hôpital Sainte-Marguerite Université de la Méditerranée Aix-Marseille II. Glaxo-Smith-Kline: cisatracurium /placebo + 18,000 €. Limites.

dotty
Télécharger la présentation

Traitements médicamenteux du SDRA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Traitements médicamenteux du SDRA Laurent PAPAZIAN Réanimation médicale Unité de Recherche en Maladies Infectieuses et Tropicales Émergentes Hôpital Sainte-Marguerite Université de la Méditerranée Aix-Marseille II Glaxo-Smith-Kline: cisatracurium/placebo + 18,000 €

  2. Limites • On parlera de • Curares • Protéine C activée • B2-mimétiques • On ne parlera pas de • Surfactant • NO • Almitrine • PGI2 • KGF • Corticoïdes • Viagra • Albumine • Furosemide • Oligo-éléments • Lipides…

  3. NMBAs use in ARDS ACURASYS LOVS LaSRS ExPress

  4. " there are no prospective, randomized, controlled trials assigning patients to a neuromuscular blocking agent versus a placebo with a goal of documenting if such patients could be managed by means other than neuromuscular blocking agent therapy "

  5. Effect of cisatracurium on oxygenation NMBA/placebo 4 ICUs – 56 patients Gainnier et al. Crit Care Med 2004

  6. Effect of cisatracurium on oxygenation p < 0.001 NMBA/placebo 4 ICUs – 56 patients Gainnier et al. Crit Care Med 2004

  7. Gainnier et al. Crit Care Med 2004

  8. Forelet al. CCM 2006

  9. Mortality ACURASYS

  10. 20 ICUs

  11. Design • Prospective, randomized, double-blind study • Open-label cisatracurium allowed according to an algorithm • Vt 6-8 ml/kg, Pplat ≤ 32 cmH2O • Inclusion criteria: PaO2:FiO2 < 150 (PEEP  5) for < 48 h cisatracuriumvs. placebo

  12. Inclusion

  13. Inclusion

  14. Mortality

  15. Mortality d90 and PaO2/FiO2

  16. Survival curve NMBA placebo • Cox multivariate proportional hazards model • - PaO2/FiO2 • Plateau pressure (predefined) • SAPS II without PaO2/FiO2 (predefined) NMBA 0.68 (0.48-0.98), p = 0.04 Plateau pressure p = 0.04 SAPS II without PaO2/FiO2 p = 0.004

  17. Ventilator-free days and alive ICU-free days

  18. No. of days without failure of nonpulmonary organs or systems,days 1 to 28

  19. Pneumothorax

  20. Time from inclusion to pneumothorax

  21. ICU-acquired muscular paresis by ICU discharge MRC score < 48

  22. Pourquoi ? • Homogénéisation ventilation régionale ? • Effet « protecteur » ? • Effet propre de la molécule ?

  23. * * BAL IL1b IL6 IL8 * Forelet al. CCM 2006

  24. Blood * IL1b IL6 * IL8 Forelet al. CCM 2006

  25. Critical Care Medicine: Volume 26(7) July 1998 pp 1290-1292 Prolonged weakness after cisatracurium infusion: A case report Davis, Neil A. PharmD; Rodgers, Jo E. PharmD; Gonzalez, Edgar R. PharmD; Fowler, Alpha A. III, MD • 45 yrs, aspiration, ARDS • d2: cisatracurium • d6-J11: solumedrol 500 mg/24h • d11: 240 mg/24h… decrease over several weeks • d13: stop cisatracurium • d30: extubation • d33: ICU discharge

  26. Independent risk factors • Women 4.66 • More than one organ dysfunction 1.28 • Duration of MV 1.1 • Corticosteroids 14.9 De Jonghe et al. JAMA 2002 Muscular paresis • NMBAs > 48 h Hansen-Flaschen et al. ARRD 93

  27. NMBA + corticosteroids • Muscular atrophy (rat) • surgical denervation + corticosteroids > corticosteroids or surgical denervation • " several critically ill patients have developed myonecrosis after administration of very high doses of NMBAs alone "(61). Rouleau et al. Muscle Nerve 87 Hund CCM 99

  28. Curares • Systématique: oui mais • PaO2/FiO2 < 150 (120 ?) • Tôt (48 premières h) • Court: 2 jours • « Curatifs » ???????

  29. Protéine C activée • Activation coagulation + suppression fibrinolyse • Dépôts de fibrine intra- et extravasculaires • Thromboses vasculaires • APC • participe à la fibrinolyse • a une activité anti-thrombotique • a une activité anti-inflammatoire

  30. Ware et al. AJP 2003

  31. Ware et al. AJP 2003

  32. Pré-traitement APC: PaO2/FiO2 Richard et al. Intensive Care Med 2007

  33. Richard et al. Intensive Care Med 2007

  34. Cytokines sériques Richard et al. Intensive Care Med 2007

  35. Protéine C activée et ALI 24 mg/kg/h for 96 h et placebo Liuet al. AJRCCM 2008

  36. Diminution de la perméabilité vasculaire • Souris VM 4h • APC à 30 et 150 min • 7 vs 20 ml/kg Vt • FR = 160/min Finigan et al. AJP 2009

  37. APC inhalée: meilleure aération Waerhaug et al. Crit Care 2009

  38. ALI/ARDS: altered alveolar clearance Ware L, Matthay M AJRCCM 2001

  39. b2-mimétiques •  clairance alvéolaire •  perméabilité endothéliale •  lésions épithéliales •  inflammation

  40. b2-mimétiques McAuley et al. CCM 2004 • HCl chez rat ventilé 4h

  41. Manocha et al. Crit Care 2006 • Rétrospective: 86 ALI • Salbutamol inhalé • 'high dose' ≥ 2.2 mg/day • 'low dose' < 2.2 mg/day Days alive and free of PaO2/FiO2 < 300 Days alive and free of ALI

  42. b2-mimétiques IV • Etude BALTI • Salbutamol IV (n=19) vs. Placebo (n=21) • Atteinte directe, 16 vs. 52% Perkins et al. AJRCCM 2005

  43. Perkins et al. AJRCCM 2005

  44. * Perkins et al. AJRCCM 2005 J7

  45. Conclusion • Traitement(s) médicamenteux du SDRA • Des conséquences • Adjuvants de la ventilation mécanique • Ont des effets secondaires

  46. Adjunctive therapies

  47. Other treatments

More Related